Meningococcal B vaccine development and evaluation of efficacy.
In this commentary we stress that serum bactericidal activity is now internationally accepted as correlate of protection for evaluating new vaccines for epidemic and endemic meningococcal B control, and that the standardization of the assay and the choice of representative strains for each of the vaccine candidates are critical.
van Alphen
Loek
L
Netherlands Vaccine Institute, Bilthoven, The Netherlands. loek.van.alphen@nvi-vaccin.nl
van den Dobbelsteen
Germie
G
D000907:Antibodies, Bacterial / Q000096:biosynthesis*; D000942:Antigens, Bacterial / Q000276:immunology; D001770:Blood Bactericidal Activity; D002986:Clinical Trials as Topic; D015195:Drug Design; D006801:Humans; D008589:Meningococcal Infections / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology*; D018272:Porins / Q000276:immunology; D011994:Recombinant Proteins / Q000276:immunology
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D022401:Meningococcal Vaccines; D018272:Porins; D011994:Recombinant Proteins; C057699:porin protein, Neisseria